690632-17-8

Usage

Uses

Used in Medicinal Chemistry:
4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1-(triisopropylsilyl)-1H-indole is used as a key intermediate in the synthesis of pharmaceutical compounds for various therapeutic applications. Its unique structure allows for the creation of new molecules with potential medicinal properties, contributing to the advancement of drug discovery and development.
Used in Material Science:
In the field of material science, 4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1-(triisopropylsilyl)-1H-indole is utilized as a component in the development of new materials with specific properties. Its incorporation into material formulations can lead to the creation of innovative products with applications in various industries.
Used in Organic Synthesis:
As a building block in organic synthesis, 4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1-(triisopropylsilyl)-1H-indole is employed for the construction of more complex organic molecules. Its unique structural features enable the synthesis of a wide range of compounds with diverse applications in research and industry.
Used in Research and Development:
4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1-(triisopropylsilyl)-1H-indole is used as a research tool in various scientific fields, including chemistry, biology, and materials science. Its unique properties and potential applications make it an interesting subject for exploration and innovation, driving the development of new technologies and materials.

InChI:InChI=1/C23H38BNO2Si/c1-16(2)28(17(3)4,18(5)6)25-15-14-19-20(12-11-13-21(19)25)24-26-22(7,8)23(9,10)27-24/h11-18H,1-10H3

Upstream product

• 13154-24-0 triisopropylsilyl chloride 
• 388116-27-6 indole-4-boronic acid pinacol ester 
• 73183-34-3 bis(pinacol)diborane 
• 52488-36-5 4-bromo-1H-indole 

Downstream Products

• 915413-24-0 N-[3-(pyridine-3-sulfonyl)-5-(1-triisopropylsilanyl-1H-indol-4-yl)-phenyl]-acetamide 
• 1292820-46-2 C₂₉H₃₇N₃O₄S₂Si 
• 915411-91-5 (6-hydroxymethyl-pyridin-3-yl)-[3-(4-methoxy-benzyloxy)-5-(1-triisopropylsilanyl-1H-indol-4-yl)-phenyl]-methanone 
• 915411-43-7 N-(3-(1H-indol-4-yl)phenyl)-N-(pyridin-3-yl)acetamide 
• 915411-31-3 [3-(4-methoxy-benzyloxy)-5-(1-triisopropylsilanyl-1H-indol-4-yl)-phenyl]-pyridin-3-yl-methanone oxime 
• 915412-21-4 [3-(4-methoxy-benzyloxy)-5-(1-triisopropylsilanyl-1H-indol-4-yl)-phenyl]-phenyl-amine 
• 1260030-08-7 N-(3-(1H-indol-4-yl)-5-(4-methoxybenzyloxy)phenyl)pyridin-3-amine 
• 1260029-93-3 3-(hydroxy(pyridin-3-yl)methyl)-5-(1H-indol-4-yl)phenol 
• 1260030-02-1 (3-(4-methoxybenzyloxy)-5-(1-(triisopropylsilyl)-1H-indol-4-yl)phenyl)(pyridin-3-yl)methanol 
• 1260030-07-6 C₃₁H₃₉N₃O₂Si 
• 915412-74-7 methyl 3-(2-chloro-6-methylisonicotinoyl)-5-(1-(triisopropylsilyl)-1H-indol-4-yl)phenylcarbamate 

Relevant academic research and scientific papers

Anti-cancer agents and uses thereof

The present invention is in the area of novel compounds and salts thereof, their syntheses, and their use as anti-cancer agents. The compounds include compounds of Formula I: and solvates, hydrates and pharmaceutically-acceptable salts thereof, wherein A1 is N or CR1; A3 is N or CR3; A5 is N or CR5; R1, R3-R6 and L are defined in the specification; n is 0 or 1; and X is an optionally-substituted aryl group having 6-10 carbons in the ring portion, an optionally-substituted 6-membered heteroaryl group having 1-3 nitrogen atoms in the ring portion, an optionally-substituted 5-membered heteroaryl group having 0-4 nitrogen atoms in the ring portion and optionally having 1 sulfur atom or 1 oxygen atom in the ring portion, or an optionally-substituted heteroaryl group in which a 6-membered ring is fused either to a 5-membered ring or to a 6-membered ring, wherein in each case 1, 2, 3 or 4 ring atoms are heteroatoms independently selected from nitrogen, oxygen and sulfur. They are effective against a broad range of cancers, especially leukemia, prostate, non-small cell lung and colon. They are additionally useful in the treatment of proliferative retinopathies such as diabetic neuropathy and macular degeneration.

ANTI-CANCER AGENTS ANS USES THEREOF

The present invention is in the area of novel compounds and salts thereof, their syntheses, and their use as anti-cancer agents. The compounds include compounds of Formula (I): and solvates, hydrates and pharmaceutically-acceptable salts thereof, wherein A1 is N or CR1; A3 is N or CR3; A5 is N or CR5; R1, R3 R6 and L are defined in the specification; n is 0 or 1; and X is an optionally-substituted aryl group having 6- 10 carbons in the ring portion, an optionally-substituted 6- membered heteroaryl group having 1- 3 nitrogen atoms in the ring portion, an optionally-substituted 5- membered heteroaryl group having 0- 4 nitrogen atoms in the ring portion and optionally having 1 sulfur atom or 1 oxygen atom in the ring portion, or an optionally-substituted heteroaryl group in which a 6- membered ring is fused either to a 5- membered ring or to a 6- membered ring, wherein in each case 1, 2, 3 or 4 ring atoms are heteroatoms independently selected from nitrogen, oxygen and sulfur. They are effective against a broad range of cancers, especially leukemia, prostate, non-small cell lung and colon. They are additionally useful in the treatment of proliferative retinopathies such as diabetic neuropathy and macular degeneration.

Anti-cancer agents and uses thereof

The present invention is in the area of novel compounds and salts thereof, their syntheses, and their use as anti-cancer agents. The compounds include compounds of Formula I: and solvates, hydrates and pharmaceutically-acceptable salts thereof, wherein A1 is N or CR1; A3 is N or CR3; A5 is N or CR5; R1, R3—R6 and L are defined in the specification; n is 0 or 1; and X is an optionally-substituted aryl group having 6-10 carbons in the ring portion, an optionally-substituted 6-membered heteroaryl group having 1-3 nitrogen atoms in the ring portion, an optionally-substituted 5-membered heteroaryl group having 0-4 nitrogen atoms in the ring portion and optionally having 1 sulfur atom or 1 oxygen atom in the ring portion, or an optionally-substituted heteroaryl group in which a 6-membered ring is fused either to a 5-membered ring or to a 6-membered ring, wherein in each case 1, 2, 3 or 4 ring atoms are heteroatoms independently selected from nitrogen, oxygen and sulfur. They are effective against a broad range of cancers, especially leukemia, non-small cell lung and colon.